In this study, we genetically modified DCs to overexpress IL-12 and GM-CSF to generate 12GM-DCs, then developed a 12GM-DC-based culture system to optimize the activation and proliferation of tumor-reactive T cells. The gene discussed is CSF2; the disease is neoplasm.